MK0462 in Treatment of Migraine With Recurrence (MK0462-022)

• Status: Completed
• Trial end date: 1996-07-01
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate rizatriptan/MK0462 (5 and 10 mg) for the treatment of acute migraine attack and treatment of up to two headache recurrences compared to placebo.

The long term extension study which pools patients from MK0462-022, -025, and -029 is described in NCT01286207.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Rizatriptan

Criteria

Inclusion Criteria:

• Patient had at least a 6-month history of migraine, with or without aura

• Patient was male, or if female must have been postmenopausal, surgically sterilized, or taking adequate contraceptive precautions

• Patient was judged to be in good health, apart from migraine

Exclusion Criteria:

• Patient was pregnant or a nursing mother

• Patient had abused drugs or alcohol within 12 months prior to entering the study

• Patient had a history of cardiovascular disease

• Patient had clinically significant ECG abnormality

• Patient had a resting systolic blood pressure of greater than 145 mm Hg or diastolic of less than 95 mm Hg at screening

• Patient received treatment with an investigational device or compound within 30 days of the study start

• Patient typically suffered from less then 1 or more than 8 attacks of migraine per month

• Patient had difficulty in distinguishing his/her migraine attacks from tension or interval headaches

• Patient had prior exposure to rizatriptan